Payment overview · 2025
General Payments
$45.74
2 reported records · 2 companies
Healthcare provider profile · identity verified
Robert P Marshburn, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COMMERCE, GA · NPI 1629184395
Verified facts
What the public records show
CMS Open Payments records show Robert P Marshburn, MD received $45.74 in general payments during 2025 across 2 reported records.
Phathom Pharmaceuticals, Inc. accounted for 58.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.87 | 58.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.87 | 41.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.74 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 472 | 123 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 458 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 89 |
| Omeprazole | Omeprazole | 400 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 359 | 65 |
| Gabapentin | Gabapentin | 340 | 46 |
| Alprazolam | Alprazolam | 315 | 47 |
| Tramadol Hcl | Tramadol Hcl | 309 | 74 |
| Lisinopril | Lisinopril | 245 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 46 |
| Famotidine | Famotidine | 218 | 29 |
| Enalapril Maleate | Enalapril Maleate | 214 | 54 |
| Carvedilol | Carvedilol | 205 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 164 | 13 |
| Trazodone Hcl | Trazodone Hcl | 160 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 151 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 145 | 23 |
| Meloxicam | Meloxicam | 142 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 136 | 17 |
| Potassium Chloride | Potassium Chloride | 133 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 129 | 29 |
| Azithromycin | Azithromycin | 123 | 87 |
| Metformin Hcl | Metformin Hcl | 123 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 36 |
| Sertraline Hcl | Sertraline Hcl | 120 | 14 |
| Eliquis | Apixaban | 119 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 119 | 56 |
| Divalproex Sodium | Divalproex Sodium | 114 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 19 |
| Finasteride | Finasteride | 110 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 109 | 14 |
| Losartan Potassium | Losartan Potassium | 105 | 26 |
| Clonazepam | Clonazepam | 102 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 100 | 28 |
| Olanzapine | Olanzapine | 98 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 20 |
| Mirtazapine | Mirtazapine | 92 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 91 | 13 |
| Atenolol | Atenolol | 88 | 26 |
| Prednisone | Prednisone | 87 | 44 |
| Lorazepam | Lorazepam | 86 | 29 |
| Furosemide | Furosemide | 81 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 78 | 13 |
| Lovastatin | Lovastatin | 77 | 15 |
| Buspirone Hcl | Buspirone Hcl | 72 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 72 | suppressed |
| Memantine Hcl | Memantine Hcl | 72 | suppressed |
| Ozempic | Semaglutide | 72 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 38 |
| Levetiracetam | Levetiracetam | 70 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 15 |
| Glipizide Er | Glipizide | 61 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 60 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 59 | 20 |
| Aripiprazole | Aripiprazole | 57 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 13 |
| Lamotrigine | Lamotrigine | 56 | suppressed |
| Simvastatin | Simvastatin | 56 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 53 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 51 | suppressed |
| Calcium Acetate | Calcium Acetate | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 14 |
| Pregabalin | Pregabalin | 50 | 15 |
| Metformin Hcl Er | Metformin Hcl | 48 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 30 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 25 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 37 | 13 |
| Promethazine Hcl | Promethazine Hcl | 37 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Estradiol | Estradiol | 35 | suppressed |
| Ezetimibe | Ezetimibe | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 11 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | 11 |
| Cefdinir | Cefdinir | 27 | 19 |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 25 | 18 |
| Fluconazole | Fluconazole | 23 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Azelastine Hcl | Azelastine Hcl | 18 | 11 |
| Sucralfate | Sucralfate | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Latanoprost | Latanoprost | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Synthroid | Levothyroxine Sodium | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.74 · 2 records | Phathom Pharmaceuticals, Inc. | TRELEGY ELLIPTA, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error